BioSpace News Archive

Brooklyn ImmunoTherapeutics LLC (NYSE American: BTX) (“Brooklyn” ) , a biopharmaceutical company currently focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer and blood disorders, today announced it has completed a $20M financing to progress the development of the mRNA gene editing and cell therapies technology recently licensed from Factor Biosciences

Sharps Compliance Corp., a leading full-service national provider of comprehensive waste management solutions including medical, pharmaceutical and hazardous, announced that Jack Holmes has resigned from the Company’s Board of Directors, effective May 21, 2021, to focus on other business commitments.

Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today announced the appointment of biotechnology industry development veteran, Franz Gerner, Ph.D., as Chief Technology Officer & Head of Manufacturing.

UroViu Corporation, the developer of a suite of portable, self-contained and versatile single-use cystoscopy solutions, has received clearance from the U.S. Food and Drug Administration to market its third device: Uro-G, a flexible single-use cystoscope

Dalrada Corporation (OTCQB: DFCO , “Dalrada”) is pleased to announce to its shareholders and the public that Dr. David Bacon, was appointed to Dalrada’s Board of Directors.

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company introducing the CellFX System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced plans to participate in the Jefferies Virtual Healthcare Conference. Management is scheduled to present at 12:30pm PT on Wednesday, June 2, 2021.

Blackstone Life Sciences, the life sciences business of Blackstone (NYSE:BX), today announced the appointments of Dr. Olivier Brandicourt, former CEO of Sanofi, Dr. Omar Ishrak, former Chairman and CEO of Medtronic, Dr. Francois Nader, former CEO of NPS Pharma, and Kim Popovits, former CEO of Genomic Health, as Senior Advisors.

Spruce Biosciences Presents Phase 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia at 23 rd European Congress of Endocrinology Richard Auchus, MD, PhD, Presents Phase 2 Data of Tildacerfont in Adult Classic CAH Tildacerfont Demonstrates Normalization of Elevated Hormone Levels Without Increases to Daily Steroid Doses

Bausch Health Companies Inc. announced that it has launched an offering of $1.6 billion aggregate principal amount of new senior secured notes due 2028.

BI 425809, A Novel Glycine transporter-1 (GlyT1) Inhibitor To Be Studied in First-of-its-Kind Phase III Trials, Incorporating Speech Analytics and Virtual Reality Functional Capacity Assessments